logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Mereo BioPharma Group plc

MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Naviā€¦ read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.34

Price

+8.79%

$0.02

$0.32

Previous Close

$0.30

Open

Premium

52w Discount
Market Cap

$54.701m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$500k

-

1y CAGR

-33.3%

3y CAGR

-50.0%

5y CAGR
Earnings

-$35.699m

+4.0%

1y CAGR

-4.2%

3y CAGR

-89.5%

5y CAGR
EPS

-$0.22

+6.9%

1y CAGR

+48.0%

3y CAGR

-47.4%

5y CAGR
Book Value

$34.054m

$40.614m

Assets

$6.560m

Liabilities

-

Debt
Debt to Assets

0.0%

-

Debt to EBITDA
Free Cash Flow

-$26.956m

+1.5%

1y CAGR

+0.6%

3y CAGR

-131.2%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.